What is the official ID of this bill?

The official print number for this legislation is S 3951.

When did the legislative process begin?

The process officially started on 2024-03-14.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/118/bills/s3951/BILLS-118s3951is.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

Who is the primary sponsor?

The primary sponsor is Sen. Casey, Robert P., Jr. [D-PA].

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Analysis and Potential Impact of S 3951

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Lowering Medicare Part D Prescription Drug Copays for Low-Income Individuals.

Q: What are the main provisions?

Key points include: Starting in 2026: Copayments for generic drugs under Medicare Part D for low-income individuals will be reduced to zero ($0). Copayments for non-generic drugs will be adjusted annually based on the consumer price index (inflation), preventing large cost spikes. Before 2026: Maximum copayments are set at $1 for generic/preferred multiple source drugs and $3 for all other drugs.

This bill aims to significantly reduce out-of-pocket costs for prescription drugs for low-income individuals enrolled in Medicare Part D. Starting in 2026, copayments for generic drugs will be eliminated entirely, while copayments for other drugs will be capped and adjusted annually based on inflation. This change provides substantial financial relief for seniors and disabled individuals needing essential medications.

Key points

Starting in 2026: Copayments for generic drugs under Medicare Part D for low-income individuals will be reduced to zero ($0).

Copayments for non-generic drugs will be adjusted annually based on the consumer price index (inflation), preventing large cost spikes.

Before 2026: Maximum copayments are set at $1 for generic/preferred multiple source drugs and $3 for all other drugs.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Cutting Copays Act

Print number: S 3951

Sponsor: Sen. Casey, Robert P., Jr. [D-PA]

Process start date: 2024-03-14

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-flash-latest

Source data: api.congress.gov

AI work logs for this document launch

Lowering Medicare Part D Prescription Drug Copays for Low-Income Individuals.

Key Questions about Lowering Medicare Part D Prescription Drug Copays for Low-Income Individuals.